| 查看: 1563 | 回复: 0 | |||
[交流]
安进与施维雅达成心血管产品合作
|
|
安进（Amgen）和施维雅（Servier）8月12日宣布，提前结束了与此2013年7月8日达成的心血管产品合作有关的《哈特—斯科特—罗迪诺反托拉斯改进法》（HSR法案）等待期，完成了该笔交易。 根据协议条款，安进获得施维雅开发的新型口服药物在美国的商业化权利，该药已以品牌名Procoralan获欧盟批准，用于慢性心脏衰竭和稳定型心绞痛患者心率升高的治疗。安进同时获得了施维雅实验性分子S38844用于心血管疾病的美国独家开发和商业化权利。目前，S38844处于II期临床开发，用于心脏衰竭的治疗。 通过合作，施维雅获得安进omecamtiv mecarbil在欧盟的独家商业化权利。omecamtiv mecarbil是一种心肌肌球蛋白（myosin）的激活剂，目前正测试用于收缩功能障碍（systolic dysfunction）患者心脏衰竭的治疗潜力。 英文原文：Amgen, Inc. : Amgen And Servier Complete Product Collaboration Transaction 08/12/2013 | 06:15pm US/EasternRecommend: 0 THOUSAND OAKS, Calif. and SURESNES, France, Aug. 12, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Servier today announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement announced on July 8, 2013, completing the transaction. Under the terms of the agreement, Amgen has obtained commercial rights in the U.S. to Servier's novel oral drug, approved in the EU as Procoralan(?) (ivabradine), for chronic heart failure and stable angina in patients with elevated heart rates. Amgen has also received an exclusive option to develop and commercialize Servier's investigational molecule, S38844, for cardiovascular diseases in the U.S. Currently, S38844 is in Phase 2 studies for the treatment of heart failure. Through the collaboration, Servier has obtained an exclusive option to commercialize omecamtiv mecarbil in Europe. Omecamtiv mecarbil is an activator of cardiac myosin, which is currently being tested for potential applications in the treatment of heart failure in patients with systolic dysfunction. |
回复此楼» 猜你喜欢
求26届aidd博导推荐
已经有4人回复
-
2026申博推荐
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有77人回复
-
一篇扩散模型的Nature Machine Intelligence论文和Elsevier上的深度学习药物书籍
已经有1人回复
-
中国药科大学2026入学博士，药物合成和设计经验，放射化学及放射医学研究
已经有25人回复
» 本主题相关商家推荐: (我也要在这里推广)
